ADM2 CRISPR/Cas9 KO Plasmid (h): sc-403726
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ADM2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ADM2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ADM2 CRISPR/Cas9 KO Plasmid (h) | sc-403726 | 20 µg | $397.00 |
Overview
ADM2 (adrenomedullin 2; also known as intermedin) encodes a secreted peptide hormone in the calcitonin gene-related peptide family that signals through CLR (CALCRL) with RAMP co-receptors to modulate cAMP/PKA-dependent responses. ADM2 contributes to vascular tone regulation, endothelial and smooth muscle cell function, fluid–electrolyte homeostasis, and stress-responsive signaling in cardiovascular and renal physiology. In cellular contexts, ADM2 can influence angiogenic programs, nitric oxide-linked pathways, and inflammatory mediator balance, integrating paracrine/autocrine cues with GPCR signaling. Dysregulated ADM2 signaling has been associated in the literature with cardiometabolic and vascular dysfunction, making it relevant for mechanistic studies in cardiovascular, renal, and immunometabolic research models.
ADM2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the ADM2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the ADM2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the ADM2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ADM2 protein expression.
This CRISPR knockout system enables efficient generation of ADM2-deficient cell models for investigation of ADM2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting ADM2 exon(s) critical for ADM2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple ADM2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ADM2 CRISPR/Cas9 KO Plasmid (h) and ADM2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the ADM2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ADM2 HDR Plasmid (h) and ADM2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by ADM2 homology arms to support homology-directed repair at defined ADM2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.